NeuroMab™ Anti-SOD1 BBB Shuttle Antibody(NRZP-1022-ZP2567)

Fig.1 binding specificity of the human antibodies to human recombinant SOD1.

h3D6v2 was as effective as chimeric 3D6 in inducing phagocytosis of Aβ aggregates from PDAPP mouse brain tissue. IgG was used as a negative control in this experiment because it is unable to bind Aβ and therefore cannot induce phagocytosis.

Fig.3 The antibody binds preferentially to misfolded / aggregated human SOD1.

h3D6v2 was as effective as chimeric 3D6 in inducing phagocytosis of Aβ aggregates from PDAPP mouse brain tissue. IgG was used as a negative control in this experiment because it is unable to bind Aβ and therefore cannot induce phagocytosis.

Fig.2 binding specificity of the human antibodies to human recombinant SOD1.

h3D6v2 was as effective as chimeric 3D6 in inducing phagocytosis of Aβ aggregates from PDAPP mouse brain tissue. IgG was used as a negative control in this experiment because it is unable to bind Aβ and therefore cannot induce phagocytosis.

Fig.4 NI-204.10D12 primarily shows SOD1 pathology as well as diffuse staining of intracellular dispersed inclusion bodies.

h3D6v2 was as effective as chimeric 3D6 in inducing phagocytosis of Aβ aggregates from PDAPP mouse brain tissue. IgG was used as a negative control in this experiment because it is unable to bind Aβ and therefore cannot induce phagocytosis.

Fig.5 NI-204.10D12 treatment can protect against motor neuron degeneration mediated by mutant SOD-1 overexpression.